BioScrip Inc (NASDAQ:BIOS)’s share price traded down 5.7% during trading on Friday . The company traded as low as $2.99 and last traded at $3.00. 4,322,598 shares changed hands during mid-day trading, an increase of 320% from the average session volume of 1,028,144 shares. The stock had previously closed at $3.18.

A number of equities analysts recently commented on the company. Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 target price on BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $3.63.

The company has a market capitalization of $382.55, a price-to-earnings ratio of -4.84 and a beta of 0.27. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million during the quarter, compared to the consensus estimate of $202.91 million. During the same quarter in the prior year, the company posted ($0.12) earnings per share. The business’s revenue for the quarter was down 11.5% compared to the same quarter last year. equities analysts expect that BioScrip Inc will post -0.63 EPS for the current fiscal year.

In other BioScrip news, CEO Daniel E. Greenleaf purchased 15,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $2.03 per share, with a total value of $30,450.00. Following the completion of the acquisition, the chief executive officer now directly owns 31,000 shares in the company, valued at $62,930. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.80% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of BIOS. Alta Fundamental Advisers LLC raised its holdings in BioScrip by 36.9% during the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock valued at $8,240,000 after acquiring an additional 818,000 shares during the period. Fuller & Thaler Asset Management Inc. bought a new stake in BioScrip during the third quarter valued at about $1,642,000. Gilder Gagnon Howe & Co. LLC raised its holdings in BioScrip by 3.6% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock valued at $43,352,000 after acquiring an additional 553,201 shares during the period. FMR LLC raised its holdings in BioScrip by 10.8% during the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock valued at $14,453,000 after acquiring an additional 520,231 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in BioScrip during the third quarter valued at about $857,000. 84.63% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “BioScrip (BIOS) Stock Price Down 5.7%” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2018/01/12/bioscrip-bios-stock-price-down-5-7.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.